Dervla M Connaughton

Dr. Dervla M Connaughton

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2024 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
CSClara Schott
Clara Schott
VLVictoria Lebedeva
Victoria Lebedeva
CTCambrie Taylor
Cambrie Taylor
SASaeed Abumelha
Saeed Abumelha
PRPavel S Roshanov
Pavel S Roshanov
DCDervla M Connaughton
Dervla M Connaughton
Key Points: Diagnostic yield of genetic testing in adults with CKD is 40%. Risk factors including positive family history and extra-kidney features associate with higher diagnostic yield, although young age at testing did not. Seventeen percent of patients who received a genetic diagnosis were reclassified into a different phenotype after testing. Background: Clinical and pathological confirmation of the diagnosis for CKD has limitations, with up to one third of individuals remaining without a formal diagnosis. Increasingly, data suggest that these limitations can be overcome by genetic testing. The objective of this study was to estimate the diagnostic yield of genetic testing in adults with CKD. Methods: Cohort studies that report diagnostic yield of genetic testing in adults with CKD published in PubMed or Embase between January 1, 2005, and December 31, 2023, were included. The Joanna Briggs Institute critical appraisal tool for prevalence studies was used to assess bias. Duplicate independent data extraction and a meta-analysis of proportions using generalized linear mixed models were completed. Results: We included 60 studies with 10,107 adults with CKD who underwent genetic testing. We found a diagnostic yield of 40% (95% confidence interval, 33 to 46); yield varied by CKD subtype with the highest yield of 62% (95% confidence interval, 57 to 68) in cystic kidney disease. Positive family history and presence of extra-kidney features were associated with higher diagnostic yield. Reclassification of the before testing diagnosis after a positive genetic testing result occurred in 17% of the solved cohort. Six studies showed the clinical benefits of genetic testing including cascade testing for family members and treatment changes. Conclusions: Overall, we show that genetic testing is informative in a high proportion of clinically selected adults with CKD. The study was limited by heterogeneity in reporting, testing technologies, and cohort characteristics. Clinical Trial registry name and registration number: International prospective register of systematic reviews (CRD42023386880).

13 November 2024 in Kidney International Reports
Verified
Journal Article
Open access
CSClara Schott
Clara Schott
MAMonica Arnaldi
Monica Arnaldi
CBCadence Baker
Cadence Baker
JWJian Wang
Jian Wang
AMAdam D. McIntyre
Adam D. McIntyre
DCDervla M Connaughton
Dervla M Connaughton
Genetic kidney disease (GKD) accounts for 10% to 20% of chronic kidney disease (CKD). Genetic testing using gene panel or targeted exome sequencing (ES) can confirm GKD; however, integration into clinical practice has been hampered by small studies, selective populations, and data predominately derived from research settings. Using prespecified clinical referral criteria and a diagnostic pipeline, we performed a prospective cohort study describing diagnostic efficacy and clinical utility of genetic assessment in patients with CKD. We analyzed a prospective cohort of 300 participants (256 families) referred to a kidney genetics clinic, between March 2020 and March 2024. Testing strategies included gene panels, and if negative or unsuitable, targeted ES analysis. Testing was performed for the detection of variants in genes known to cause CKD. We identified a causative variant in 33% of families (85/256). Diagnostic yield increased from 23% (n = 70/300) from gene panel alone, to 34% (n = 103/300) with comprehensive testing. The median time from first diagnosis of CKD to genetic assessment was long at 10.4 years. Following genetic assessment, the median time to receive a positive genetic result was 2.9 months. Multiple levels of clinical utility were recorded in patients receiving a genetic diagnosis, varying across CKD subtype. Instituting referral guidelines and a standardized testing algorithm established a genetic diagnosis in one-third of participants, providing insight into the viability of integrating genetic assessment in the CKD diagnostic pathway. Considering the potential for clinical utility, strategies to reduce the time from CKD diagnosis to genetics assessment are needed.

27 December 2022 in Frontiers in Urology
Verified
Journal Article
Open access
CSClara Schott
Clara Schott
APAva Pourtousi
Ava Pourtousi
DCDervla M Connaughton
Dervla M Connaughton
Nephrolithiasis is a condition in which crystals precipitate out of the urine forming kidney stones in the renal calyces and pelvis. Approximately 80% of stones are composed of calcium oxalate and calcium phosphate. In recent years, there has been a significant increase in the prevalence of nephrolithiasis across populations, specifically in that of the pediatric population. The etiology of stone disease is multifactorial, and includes environmental, dietary, hormonal, and genetic factors. Evidence for monogenic causation (also known as Mendelian or single-gene disorders) in nephrolithiasis includes the finding that 30% of children with stone disease report a positive family history, with monogenic nephrolithiasis accounting for approximately 30% of cases. Monogenic nephrolithiasis can occur in isolation or may be the result of an underlying genetic disorder including autosomal dominant hypocalcemia (ADH), primary hyperoxalurias, and hereditary hypophosphatemic rickets with hypercalciuria (HHRH), to name a few. Currently, there are 41 known genes that represent monogenic causes of human nephrolithiasis. Since early detection of these mutations can in some cases prevent the progression to end stage kidney disease in pediatric patients, establishing the genetic basis for nephrolithiasis is increasingly important. Here we provide an overview of kidney stone disease in children with a focus on monogenic causation in the pediatric population.

27 June 2024 in Gene
Verified
Journal Article
Open access
CSClara Schott
Clara Schott
ADAllison Dilliott
Allison Dilliott
JWJian Wang
Jian Wang
AMAdam D. McIntyre
Adam D. McIntyre
SSSurim Son
Surim Son
DCDervla M Connaughton
Dervla M Connaughton
Vascular calcification is prevalent in chronic kidney disease (CKD). Genetic causes of CKD account for 10-20% of adult-onset disease. Vascular calcification is thought to be one of the most important risk factors for increased cardiovascular morbidity and mortality in CKD patients and is detectable in 80% of patients with end stage kidney disease (ESKD). Despite the high prevalence of vascular calcification in CKD, no single gene cause has been described. We hypothesized that variants in vascular calcification genes may contribute to disease pathogenesis in CKD, particularly in families who exhibit a predominant vascular calcification phenotype. We developed a list of eight genes that are hypothesized to play a role in vascular calcification due to their involvement in the ectopic calcification pathway: ABCC6, ALPL, ANK1, ENPP1, NT5E, SLC29A1, SLC20A2, and S100A12. With this, we assessed exome data from 77 CKD patients, who remained unsolved following evaluation for all known monogenic causes of CKD. We also analyzed an independent cohort (Ontario Neurodegenerative Disease Research Initiative (ONDRI), n = 520) who were screened for variants in ABCC6 and compared this to a control cohort of healthy adults (n = 52). We identified two CKD families with heterozygous pathogenic variants (R1141X and A667fs) in ABCC6. We identified 10 participants from the ONDRI cohort with heterozygous pathogenic or likely pathogenic variant in ABCC6. Replication in a healthy control cohort did not reveal any variants. Our study provides preliminary data supporting the hypothesis that ABCC6 may play a role in vascular calcification in CKD. By screening CKD patients for genetic causes early in the diagnostic pathway, patients with genetic causes associated with vascular calcification can potentially be preventatively treated with new therapeutics with aims to decrease mortality.

26 March 2026 in Kidney International
Verified
Journal Article
Open access
CSClara Schott
Clara Schott
SRSydney Relouw
Sydney Relouw
MAMonica Arnaldi
Monica Arnaldi
CBCadence Baker
Cadence Baker
GOGabriela Offerni-Almada
Gabriela Offerni-Almada
DCDervla M Connaughton
Dervla M Connaughton
The cause of kidney failure in kidney transplant recipients remains unknown in 20-45% of cases. Outcomes for living kidney donors (LKDs) are generally excellent, with only 8% experiencing complications post-donation. Here, we hypothesize that genetic testing could identify a genetic etiology in at least 20% of recipients and inform risk stratification in LKDs. Genetic testing was performed in 231 transplant recipients and 46 prospective LKDs by means of exome sequencing of 409 chronic kidney disease (CKD)-associated genes. We also assessed 122 retrospective LKDs who developed adverse kidney outcomes post-donation which were defined by at least two of the three criteria: hypertension, a glomerular filtration rate under 60 mL/min/1.73m2, or a urine albumin to creatinine ratio of 3 mg/mmol or more. Pathogenic or likely pathogenic (P/LP) variants were identified in 23% of recipients, most commonly involving genes associated with cystic kidney disease and glomerulopathies. Among the recipients with a genetic diagnosis, there was a 37% rate of reclassification to a different phenotype post genetic testing. Among prospective LKDs, 4% had P/LP variants. In the retrospective cohort of LKDs with adverse kidney outcomes post donation, 19% carried P/LP variants. Genetic testing yielded a high diagnostic rate and frequently reclassified CKD etiology in transplant recipients, underscoring its diagnostic utility. Universal genetic testing of asymptomatic LKDs had a yield of 4%, although our prospective LKD cohort had limited sample size. In contrast, high proportion of LKDs with adverse kidney outcome post-donation were found to carry P/LP variants in CKD-associated genes. Our findings suggest that targeted genetic testing of high-risk donors may be a preferred over universal testing strategy to optimize donor selection in LKDs. However, further evaluation is warranted to ensure this approach appropriately balances donor safety with equitable access.

4 July 2025 in Genetics in Medicine Open
Verified
Journal Article
Open access
ADAngela Du
Angela Du
KLKaitlyn Lemay
Kaitlyn Lemay
ABAmit Bagga
Amit Bagga
PBPriya T. Bhola
Priya T. Bhola
PBPierre Antoine Brown
Pierre Antoine Brown
AGAndrea Guerin
Andrea Guerin
Genetic causes account for 10% to 20% of adult and 30% to 50% of pediatric chronic kidney disease (CKD). Patients with genetic CKD have a higher risk of progression to kidney failure. More than 500 genes are implicated in kidney disease; yet, Ontario’s existing gene panel options includes fewer than 45 genes. Despite growing evidence for genetic testing in CKD care, testing is not systematically integrated into the diagnostic pathway. Standardized testing and clear eligibility criteria are needed to improve diagnosis, care, and outcomes. In 2023, Ontario Health’s Provincial Genetics Program convened a Renal Genetics Expert Group to develop standardized genetic testing criteria and evidence-based multigene panels for CKD. This initiative aims to support equitable access to high-quality genetic services and improve clinical outcomes through early, accurate diagnoses. An environmental scan of provincial, national, and international guidelines informed the development of a testing framework. Literature review and expert consensus guided the creation of eligibility criteria and panel content. Input from nephrologists, geneticists, genetic counsellors, and patients was incorporated throughout the process. Standardized recommendations for genetic testing in CKD promote consistent, equitable access to diagnostics across Ontario. Careful curation of multigene panels that align with current knowledge of gene-disease associations and patient phenotypes, can help streamline testing. Integration of this framework into clinical care will strengthen collaboration between nephrology and genetics, facilitate earlier diagnosis, and support personalized management, ultimately improving outcomes for individuals with CKD.